March 2, 2010

Radhakrishnan   Cattran   Kopp

The Changing Face of FSGS/MCD    Jai Radhakrishnan, MD; Daniel C. Cattran, MD; and Jeffrey B. Kopp, MD (ASN Renal Week Clinical Nephrology Conference, November, 2009.) Radhakrishnan: How should we treat minimal change disease on initial presentation? How should we treat patients who are frequent relapsers? Those who are refractory to therapy? Should treatment be changed for the C1Q and IgM variants? How is adult MCD different from that in children? Cattran: What is the value of achieving partial remission in FSGS? Should initial treatment still be steroids, especially in older patients, or obese patients? If not, what might be alternatives for initial treatment? What do the other options include? Is cyclosporin the best? What about tacrolimus? MMF? Rituximab? Pirfenidone? Kopp: In treating FSGS, is pulse oral dexamethasone and alternative to daily steroids? What are the results with rituximab or adalimumab in treating FSGS? Is there a role for pirfenidone, for rosiglitazone, and for retinoids such as isotretinoin? What do the preliminary results show?

ANNA CE (Article Free, $CE) ANNA CE (NNJ) Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN. Quality of Life in Patients Undergoing Hemodialysis and Renal Transplantation A Meta-Analytic Review (Vol 37/No. 1. Expires 2/20/2012) Kandace Landreneau, PhD, RN, CCTC, Kathryn Lee, PhD, RN, FAAN, and Michael D. Landreneau, MD 1.3 hr The Dual Vitamin D Pathways: Considerations for Adequate Supplementation (Vol 37/No. 1. Expires 2/20/2012) Susan C. Cronin, MS, RN 1.4 hr Seeking Optimal Renal Replacement Therapy Delivery in Intensive Care Units (Vol 37/No. 1. Expires 2/20/2012) Marinka Kocjan, MN, RN, CNCC(C), and Fabrice P. Brunet, MD, FRCPC 1.3 hr

ASN Renal Week 2009 now in MP3

AUDIOFILE LIST (ASN Renal Week 2009) (23 talks) Sex and the Kidney P. August, S.B. Ahmed, S.A. Karumanchi, and J.A. Miller Multiple Myeloma G.A. Herrera, P.M. Voorhees, F. Madore, J.A. Katzmann Management of Hyponatremia R.H. Stenrs, H.J. Adrogue, J.G. Verbalis The Approaching Tidal Wave of Hypertension and Its Sequelae in the Young B. Falkner, S.R. Daniels, J.T. Flynn, R-E. W. Kavey The Kidney in End Stage Liver Disease R.W. Schrier, T.A. Gonwa, A. Davenport, and P-Y. Fan Renal Diseases of Children in Adults M.E. Ferris, F. Hildebrandt, R.L. Chevalier, and S. Goldstein

Did you miss these recent slide/audio lectures? Hepatitis C and Renal Disease    Roy D. Bloom, MD and Robert S. Brown, Jr, MD (ASN Renal Week Clinical Nephrology Conference, November, 2009.) Bloom: What are the characteristics of transplant candidates infected with hepatitis C? What is the impact of HCV infection on patient and graft survival? On hepatic complications? On new onset diabetes (NODAT)? Glomerulonephritis? Infection? Does liver disease progress after transplantation? What is the role of pretransplant interferon? What are useful patient management algorithms? Brown: What are the goals of antiviral therapy of HCV? How durable is a sustained virologic response? How is this affected by duration of interferon therapy and dosage of ribavirin? How is treatment different in genotype 1 vs. 2 and 3 disease? What should be the virologic monitoring strategy? What are issues of using interferon and especially, ribavirin, when renal function is decreased? What are the complications? What is the data with emerging therapies for HCV, including polymerase and proteinase inhibitors? What is the role of triple therapy? Re-treatment? Primary Care for Nephrologists: HIV Nephropathy    Arthur H. Cohen, MD; and Jeffrey S. Berns, MD (ASN Renal Week Clinical Nephrology Conference, November, 2009.) Cohen: What are the nephropathies directly related to HIV infection? How have they changed in the era of HAART? What happened to the tubuloreticular inclusions? Tubular microcystic dilatation? ATN-like lesions? What about those related to complications of HIV? How does the immune complex-like lesion relate to HIV infection? What is the pathogenesis of the lupus-like lesions in HIV? What characterizes indinavir and tenofovir nephrotoxicities? Dr. Berns: What are the pitfalls of assessing GFR in patients with HIV? Why should cystatin estimates be avoided? What has follow-up data been on efficacy of ACE inhibitors and HIVAN? Under which conditions, if any, might corticosteroid treatment be considered? How does one approach TTP/TMA in HIV-infected patients? Are there any substantial access-related issues in hemodialysis patients with HIV? ASN Renal Week 2009 now in MP3 AUDIOFILE LIST (ASN Renal Week 2009) (52 talks) Is Peritoneal Dialysis Membrane Failure Inevitable with Long-term Use? A. Breborowicz, W Van Biesen, S. K. Mujais, and B. Lindholm Important Clinical Trials in Transplantation H. Ekberg, F. G. Vincenti, J. D. Schold, and S. M. Flechner Diabetic Nephropathy A. K. Mottl, M. E. Williams, J. Lewis, and K. R. Tuttle Update in Acute Kidney Injury (AKI) S. S. Waikar, P. W. Eggers, S. Goldstein, and P. M. Palevsky The Importance of Proteinuria as a Surrogate for Outcome in CKD T. H. Hostetter, A. M. Thompson, G. Remuzzi, D. De Zeeuw and T. H. Greene Quotidian (Daily) Dialysis A. S. Kliger, C. T. Chan, M. L. Unruh, and B. J. Manns Nephrology Quiz & Questionnaire J. M. Bargman, B. F. Palmer, M. D. Samaniego-Picota, and F. C. Fervenza Glomerular Injury in Progressive Renal Disease S. G. Adler, J. C. Jennette, E. Ritz, and J. F. Bertram Debates in Renal Disease 2: Combination of ACEI and ARB is More Efficacious than Monotherapy H. Paraving, and J. F. Mannr Vascular Calcification S. E. Rosas, P. Raggi, M. J. Budoff, and M. Ketteler Thrombotic Microangiopathies J. E. Sadler, G. B. Appel, W. F. Clark, and C. Licht The Changing Face of FSGS/MCD M. Kretzler, J. Radhakrishnan, D. C. Cattran, and J. B. Kopp Infectious Risk in Renal Replacement Therapy N. D. Vaziri, A. J. Collins, N. R. Powe, and C. E. Lok

HDCN home /about our site / subscribe to key zone / register for free zone
update email address / subscription status / forget your password?